Onconetix, Inc. Share Price

ONCO

US68237Q4010

Pharmaceuticals

Real-time Estimate Cboe BZX 01:27:35 29/10/2026 am IST			5-day change	1st Jan Change
0.5940 ^USD	+25.16%		+16.78%	-99.39%

08/10	RBC Raises Price Target on Onconetix to $459 From $450, Keeps Outperform Rating	MT
24/09	SRX Global Inc. acquired an unknown minority stake in Onconetix, Inc..	CI

Last Transcript: Onconetix, Inc.

Onconetix, Inc., Realbotix Corp. - M&A Call

14/02

More transcripts

Analysts' recommendations: Onconetix, Inc.

08/10	RBC Raises Price Target on Onconetix to $459 From $450, Keeps Outperform Rating	MT
13/23/13	Maxim Downgrades Blue Water Biotech to Hold From Buy	MT
26/23/26	HC Wainwright Adjusts Price Target on Blue Water Biotech to $9 From $7, Maintains Buy Rating	MT
08/22/08	Maxim Starts Blue Water Vaccines at Buy With $4 Price Target	MT

More recommendations

Press Releases: Onconetix, Inc.

24/09	SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)	AQ
14/09	Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition	AQ
03/09	Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events	AQ
06/08	Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series	AQ
05/08	Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG	AQ

More press releases

News in other languages: Onconetix, Inc.

04/22/04

++ Analysen des Tages von Dow Jones Newswires (04.04.2022) +++

More news

Managers and Directors: Onconetix, Inc.

Manager	Title	Age	Since
David White CEO	Chief Executive Officer	73	18/03/2026
Karina Fedasz CEO	Chief Executive Officer	53	02/04/2025

Director	Title	Age	Since
Sarah Romano BRD	Director/Board Member	46	05/12/2025
Sammy Dorf CHM	Chairman	41	23/04/2026
Joshua Epstein BRD	Director/Board Member	47	23/04/2026

More insiders

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for menâ€™s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patientâ€™s regular Prostate-Specific Antigen (PSA) test.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
27/26/27	$0.4746	+18.92%	25,15,473
26/26/26	$0.3991	-4.52%	8,29,935
23/26/23	$0.4180	+2.75%	5,72,991
22/26/22	$0.4068	-6.53%	5,54,721
21/26/21	$0.4352	+7.09%	6,89,247

End-of-day quote Nasdaq

More quotes

Market Cap	18.74L 16.82L 15.55L 14.08L 26.31L 18Cr 26.62L 1.86Cr 74.04L 9.34Cr 70.33L 68.85L 30Cr	P/E 2024 *	-	P/E 2025	-0.09x
Enterprise Value	-32.98L -29.59L -27.35L -24.77L -46.28L -31Cr -46.84L -3.27Cr -1.3Cr -16Cr -1.24Cr -1.21Cr -52Cr	EV / Sales 2024	55,56,319x	EV / Sales 2025	-33,67,890x
Free-Float	88.93%	Yield 2024 *	-	Yield 2025	-

08/10	RBC Raises Price Target on Onconetix to $459 From $450, Keeps Outperform Rating	MT
24/09	SRX Global Inc. acquired an unknown minority stake in Onconetix, Inc..	CI
24/09	SRX Global Makes Investment in Onconetix	MT
01/09	White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies	MT
14/08	Onconetix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
28/07	Onconetix, Inc. announced that it expects to receive $780.2496 million in funding	CI
19/05	Onconetix, Inc. announces 1-for-10 reverse stock split	RE
19/05	Realbotix provides update on Nasdaq listing	RE
13/05	Onconetix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
25/04	Onconetix Inc Andrew Oakley resigns as chairman of board	RE
25/04	Onconetix, Inc. Announces Board and Committee Changes	CI
31/03	Onconetix appoints David White as chief executive officer and Sammy Dorf as member of the board of directors	RE
25/03	Onconetix on March 18 appointed David White as CEO, effective as of that date	RE

1 day	+18.92%
1 week	+16.78%
Current month	-39.33%
1 month	-53.92%
3 months	-41.69%
6 months	-93.60%
Current year	-99.39%

1 week	0.34	0.48
1 month	0.34	1.07
Current year	0.34	115
1 year	0.34	200
3 years	0.34	90,949.27
5 years	0.34	1,54,52,876.38
10 years	0.34	1,54,52,876.38

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/04/26	HRT Financial LP	Sell	Company	49,710	7.1739%
14/04/26	HRT Financial LP	Other	Company	1,04,498	15.0807%
14/04/26	HRT Financial LP	Sell	Company	1,82,965	26.4047%

Onconetix, Inc. Share Price

Stocks

ONCO

US68237Q4010

Pharmaceuticals

Valuation: Onconetix, Inc.

Chart: Onconetix, Inc.

Latest news: Onconetix, Inc.

Last Transcript: Onconetix, Inc.

Analysts' recommendations: Onconetix, Inc.

Press Releases: Onconetix, Inc.

News in other languages: Onconetix, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Onconetix, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCONETIX, INC.	+25.16%	+16.78%	-99.73%	-100.00%	18.74L
ELI LILLY AND COMPANY	+0.50%	+1.38%	+57.09%	+127.73%	1,14300Cr
JOHNSON & JOHNSON	+0.86%	+5.14%	+45.00%	+84.34%	65TCr
ABBVIE INC.	-0.14%	+0.42%	+25.69%	+101.56%	51TCr
ROCHE HOLDING AG	-0.05%	+2.28%	+49.14%	+67.74%	38TCr
MERCK & CO., INC.	-0.63%	-5.97%	+61.93%	+37.25%	35TCr
NOVARTIS AG	+0.34%	+2.15%	+25.26%	+54.27%	29TCr
ASTRAZENECA PLC	-0.45%	+1.16%	+1.74%	+26.08%	26TCr
AMGEN INC.	+0.87%	+3.08%	+54.69%	+71.67%	24TCr
GILEAD SCIENCES, INC.	+0.08%	+3.67%	+35.05%	+104.71%	20TCr
Average	+2.37%	+1.67%	+25.59%	+57.54%	40.28TCr
Weighted average by Cap.	+0.79%	+0.71%	+43.68%	+87.36%

	2024	2025
Net sales	2.52 2.26 2.09 1.9 3.54 240.4 3.59 25.03 9.97 125.8 9.47 9.27 399.36	0.82 0.73 0.68 0.61 1.14 77.66 1.16 8.09 3.22 40.64 3.06 3 129
Net income	-5.87Cr -5.27Cr -4.87Cr -4.41Cr -8.24Cr -558.98Cr -8.34Cr -58Cr -23Cr -292.5Cr -22Cr -22Cr -928.59Cr	-1.4Cr -1.26Cr -1.16Cr -1.05Cr -1.97Cr -133.65Cr -1.99Cr -14Cr -5.54Cr -70Cr -5.27Cr -5.15Cr -222.01Cr
Net Debt	88.01L 78.96L 73L 66.12L 1.24Cr 84Cr 1.25Cr 8.73Cr 3.48Cr 44Cr 3.3Cr 3.23Cr 139.25Cr	-51.72L -46.4L -42.9L -38.85L -72.59L -49Cr -73.47L -5.13Cr -2.04Cr -26Cr -1.94Cr -1.9Cr -82Cr